Syndax Pharmaceuticals (SNDX) - Uzoq muddatli qarzning kapitalga nisbati

Syndax Pharmaceuticals (SNDX) korporativ emblemasi va logotipi

Syndax Pharmaceuticals (SNDX) kompaniyasining tarixiy narxlar dinamikasi biznesning FDA qat'iy nazoratiga va klinik sinovlarning ulkan xarajatlariga nisbatan barqarorligini baholash imkonini beradi. Kompaniyaning o'sishi Niktimvo dori vositasining joriy etilishi va Revumenib ishlab chiqilishiga bog'liq. Ushbu ko'rsatkichning joriy qiymati 40.07 ni tashkil etadi, bu esa yangi o'simtaga qarshi agentlarni bozorga chiqarish uchun marketing va R&D ga yo'naltirilgan rejalashtirilgan likvidlik xarajatlari uchun juda muhimdir.

Syndax - SNDX Uzoq muddatli qarzning kapitalga nisbati (davr: 04.07.2022 - 31.10.2026)

Syndax Pharmaceuticals kompaniyasining tahliliy kesimlari

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Syndax Pharmaceuticals Inc|SNDX - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Syndax Pharmaceuticals, Inc.|SNDX - Kompaniyaning to‘liq qiymati
- kompaniyaning balans qiymati tafsilotlari:
Bitta aksiya hisobiga xususiy kapital Syndax Pharmaceuticals|SNDX - Balans kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati syndax.com|SNDX - Kompaniyaning umumiy aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Syndax Pharmaceuticals|SNDX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati syndax.com|SNDX - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Syndax Pharmaceuticals, Inc.|SNDX - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzi Syndax Pharmaceuticals|Tezkor likvidlik syndax.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
SNDX - Kompaniyaning sof foydasi
Kompaniyaning umumiy tahlili:Syndax Pharmaceuticals Inc - SNDX
syndax.com original mahsuloti

Ushbu koeffitsiyent uzoq muddatli majburiyatlarning kapitalga nisbatan ulushini o'lchaydi, bu esa investorlarga moliyaviy leveraj darajasini va kredit defolti xavfini baholash imkonini beradi. Kapitaldagi uzoq muddatli qarz yuklamasi darajasini tahlil qilish orqali, Syndax Pharmaceuticals (SNDX) taqsimot markazlarini optimallashtirish yo'li bilan operatsion rentabellikni saqlab qolgan holda, kamyob dori vositalarini yetkazib berish uchun xavfsiz logistika tarmoqlari rivojlantirilishini qanday moliyalashtirayotganini tushunish mumkin.

Muhim raqobatchilar

Uzoq muddatli qarzning o'z kapitaliga nisbati TG Therapeutics Inc (TGTX)|Uzoq muddatli qarzning kapitalga nisbati ACLX|Uzoq muddatli qarzning kapitalga nisbati Disc Medicine Pharma (IRON)|Uzoq muddatli qarzning o'z kapitaliga nisbati Kura Oncology, Inc. KURA|ADCT: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Foghorn - Uzoq muddatli qarzning kapitalga nisbati|Vor Biopharma, Inc. (VOR) - Uzoq muddatli qarzning o'z kapitaliga nisbati|NKTX: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Coeptis Therapeutics, Inc. (COEP)|Uzoq muddatli qarzning o'z kapitaliga nisbati Actinium Pharmaceuticals|ESLA: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati CASI (CASI Pharmaceuticals)|MRKR (markertherapeutics.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati INAB (IN8bio, Inc)|Eterna Therapeutics, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|GTBP - Uzoq muddatli qarzning o'z kapitaliga nisbati|APTO: Uzoq muddatli qarzning o'z kapitaliga nisbati|Bio-Path Holdings, Inc. (BPTH) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati MEI Pharma Inc (MEIP)|Uzoq muddatli qarzning o'z kapitaliga nisbati Vincerx Pharma Inc.